Cholangiocarcinoma

Results of the retrospective analysis of phase 2 study of the FGFR1-3 selective tyrosine kinase inhibitor infigratinib indicate that efficacy outcomes in patients with CCA and FGFR2 fusions were better with third- or later-line infigratinib therapy compared with standard second-line chemotherapy.

Retrospective analysis data indicate that adjuvant chemoradiotherapy was associated with improved survival compared with chemotherapy alone in patients with extrahepatic CCA.

Comprehensive genomic profiling of tumor tissue and cfDNA of patients enrolled in the phase 2 study of infigratinib underscored the heterogeneity of CCA and the potential clinical utility of cfDNA to identify FGFR2 fusions.

Detection of IDH1 mutations in plasma from patients with intrahepatic cholangiocarcinoma is highly concordant with detection in tumor tissue.

In a phase 2 trial of patients with cholangiocarcinoma and FGFR2 fusions, infigratinib administered as third- and later-line chemotherapy treatment resulted in a meaningful progression-free survival and objective response rate benefit.

The clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations are reported based on a retrospective chart review.

Liquid biopsies may offer the opportunity to obtain information regarding specific genetic mutations in intrahepatic cholangiocarcinoma.

At the First Annual Cholangiocarcinoma Summit, presenters discussed recent advances in the management of patients with cholangiocarcinoma (CCA).

Data from the single-arm, open-label phase 2 clinical trial FIGHT-202, which was presented at the ESMO Congress 2019, revealed that investigational pemigatinib induced a response in 35.5% of the 107 patients with FGFR2 fusions or rearrangements (cohort A), with a median duration of response of 7.5 months.